Jeckelmann, Jean-Marc
Lemmin, Thomas
Schlapschy, Martin
Skerra, Arne
Fotiadis, Dimitrios
Funding for this research was provided by:
University of Bern, Switzerland
Bern University Research Foundation, Switzerland
National Centre of Competence in Research (NCCR) TransCure
Swiss National Science Foundation, Switzerland (194606)
Article History
Received: 12 July 2022
Accepted: 27 October 2022
First Online: 30 October 2022
Competing interests
: Arne Skerra is founder and shareholder of Pieris Pharmaceuticals, Inc. All other authors declare no conflict of interest.